Toronto, Ontario--(Newsfile Corp. - February 26, 2026) - QScreen AI Inc (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening and employee wellness, is pleased to announce a non-brokered private placement. The Company intends to issue (the "Offering") of up to 10,000,000 units (each, a "Unit") at a price of C$0.05 per Unit, for aggregate gross proceeds to the Company of up to C$500,000.Each Unit will be comprised of one common share of the Compan ...

Toronto, Ontario--(Newsfile Corp. - February 9, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), a pioneering leader in artificial intelligence enabled health and safety technology, is pleased to announce that it has entered into an independent contractor agreement with Global Frontier Advisors L.P. ("GFA"), effective January 30, 2026. GFA will receive a combination of equity-based along with performance-based compensation during the term of the agreement, subject to applicable regulatory a ...

Core Viewpoint - QScreen AI Inc. has officially changed its name from Predictmedix AI Inc. to better reflect its evolution into a broader screening and decision-intelligence platform, enhancing its market positioning and technology alignment [1][5][7]. Company Overview - QScreen AI Inc. is a provider of rapid health screening and remote patient care solutions globally, utilizing AI-powered Smarthealth AI stations to analyze physiological data and predict various health issues [8]. Name Change Details - The company's common shares will begin trading under the new symbol (CSE: QAI) on the Canadian Securities Exchange starting January 27, 2026, with no changes to share capital, business operations, or management [2][3][4]. Technological Evolution - The transition to QScreen AI Inc. signifies the company's advancement beyond traditional AI architectures, incorporating quantum-inspired and advanced computational techniques to enhance data processing and analysis [6][7]. Strategic Focus - The company aims to commercialize advanced, quantum-enhanced AI capabilities across healthcare, safety, and other high-value markets, with a focus on scaling and market penetration [7].

Core Insights - Predictmedix AI Inc. has been selected for the Official Canada Trade Mission to Mexico, highlighting its status as a leader in AI-enabled health and safety technology [1][4][11] Group 1: Trade Mission Details - The trade mission is scheduled for February 15–20, 2026, focusing on key cities such as Mexico City, Guadalajara, and Monterrey [1] - This elite delegation includes only the most export-ready Canadian innovators, aligning with Canada's strategic priorities for global commercial alliances [2] - The mission is led by the Honourable Dominic LeBlanc, Minister responsible for Canada-U.S. Trade, and aims to provide access to Mexican business leaders and government decision-makers [3] Group 2: Strategic Importance - Participation in the trade mission validates Predictmedix's commercial maturity and international market appeal [4][11] - The mission supports Canada's national agenda for export diversification and innovation leadership, coinciding with growing economic momentum with Mexico [6] - Mexico's market, with over 130 million people, offers tariff-free access under CUSMA, making it an ideal location for technology deployment [5] Group 3: Technological Advancements - Predictmedix is emphasizing its integration of quantum-inspired algorithms into its AI framework, enhancing data processing speeds and diagnostic precision [7][9] - The company is onboarding industry veterans to lead its regional distribution network, leveraging their relationships in Mexico's healthcare and industrial sectors [10] Group 4: Commercial Objectives - The mission aims to expand Predictmedix's international sales pipeline and secure high-impact distribution partners [8] - The company is positioned to capitalize on high-growth sectors such as advanced manufacturing, ICT and AI, cleantech, and clean energy [6]

Core Viewpoint - Predictmedix AI Inc. has successfully closed the final tranche of its non-brokered private placement, raising a total of $612,650 across all tranches, indicating strong investor interest and strategic alignment with long-term goals [2][3][5]. Group 1: Financial Details - In the final tranche, the company issued 3,050,000 units at a price of $0.05 per unit, resulting in gross proceeds of $152,500 [3][4]. - The total capital raised from all tranches of the offering amounts to $612,650 [3]. Group 2: Warrant Information - Each unit consists of one common share and one half of a common share purchase warrant, with each warrant allowing the purchase of one half common share at a price of C$0.15 for 36 months [4]. - If the volume weighted average price of the common shares reaches or exceeds $0.30 for 10 consecutive trading days, the company may accelerate the expiry date of the warrants [4]. Group 3: Strategic Approach - The company emphasized a disciplined, value-focused approach to the financing, prioritizing strategic contributions from investors over merely maximizing capital [5]. - The completion of this financing is expected to provide clarity and momentum for advancing initiatives in key markets [5]. Group 4: Company Overview - Predictmedix AI Inc. is an emerging provider of rapid health screening and remote patient care solutions, utilizing AI technology to analyze physiological data and predict health issues [6]. - The company's Smarthealth AI stations can assess 19 physiological vital parameters and detect impairments due to drugs, alcohol, fatigue, or mental illnesses [6].

Core Viewpoint - Predictmedix AI Inc. successfully closed the first tranche of its non-brokered private placement, raising gross proceeds of $460,150 by issuing 9,203,000 units at a price of $0.05 per unit, indicating strong internal confidence in the company's future growth and innovation [1][2]. Financing Details - The private placement consisted of 9,203,000 units, each comprising one common share and one half of a common share purchase warrant, raising a total of $460,150 [2]. - Insiders subscribed $60,000 of the tranche, with Sheldon Kales and Dr. Rahul Kushwah each investing $30,000, reflecting confidence in the company's prospects [1][3]. - Each warrant allows the holder to purchase one half of a common share at a price of C$0.15 for 36 months, with potential acceleration of expiry if the share price meets certain conditions [2]. Regulatory Context - The insider participation in the private placement is classified as a "related party transaction" under Multilateral Instrument 61-101, with the company relying on exemptions from valuation and minority shareholder approval requirements [3]. Strategic Engagement - This financing round follows Predictmedix's active engagement with European capital markets, including participation in the 25th MK Investment Conference in Munich, aimed at expanding its shareholder base and building relationships with global investors [5]. - The company has also conducted a high-profile European road-show to engage influential family offices and institutional investors [5]. Company Overview - Predictmedix AI Inc. is an emerging provider of rapid health screening and remote patient care solutions, utilizing AI technology to analyze physiological data and predict various health issues [6]. - The company's Smarthealth AI stations can assess 19 physiological vital parameters and detect impairments due to drugs or alcohol, fatigue, or mental illnesses [6].

Core Viewpoint - Predictmedix AI Inc. is proposing a non-brokered private placement to raise up to C$900,000 by issuing up to 18,000,000 units at a price of C$0.05 per unit [1][2] Capital Raising and Use of Proceeds - The offering consists of units that include one common share and one half of a common share purchase warrant, with warrants allowing the purchase of additional shares at C$0.15 for 36 months [2] - The capital raised will enhance Predictmedix's core AI technology and support ongoing initiatives across its product ecosystem [3] Strategic Direction - The company is focused on advancing its Predictmedix Core AI Engine, which underpins multiple growth verticals, including AI-powered clinical trial applications, SmartHealth AI station certification initiatives, and B2C vital-scanning mobile platform development [3][8] Recent Corporate Activity - Following participation in the 25th MK Investment Conference in Munich, Predictmedix engaged with global investors and partners who showed strong interest in its AI-driven healthcare innovations [4][5] Company Overview - Predictmedix AI Inc. is a provider of rapid health screening and remote patient care solutions, utilizing AI technology to analyze physiological data and predict various health issues [6]

Core Insights - Predictmedix AI Inc. has launched a Clinical-Trial AI Platform aimed at enhancing efficiency in the $70 billion clinical trials market by helping pharmaceutical sponsors and contract research organizations (CROs) model, plan, and adapt clinical trials more effectively [1][4]. Company Overview - Predictmedix AI Inc. is an emerging leader in AI-powered health and safety technology, focusing on rapid health screening and remote patient care solutions globally [9]. - The company utilizes SmartHealth AI Stations, which employ multispectral cameras to analyze physiological data patterns and predict various health issues [9]. Product Features - The Clinical-Trial AI Platform is built on patented technology and high-fidelity datasets, designed to function as a real-time digital support system for trial planning [2]. - Key features include: - Adaptive Simulation Engine for running "what-if" scenarios and updating projections based on new data [6]. - Patient-Site Optimization to improve recruitment and reduce dropouts through AI recommendations [6]. - Cost & ROI Modeling to estimate budget impacts alongside predicted clinical outcomes [6]. - Interactive Dashboards for visualizing risk, cost, and patient flow [6]. - Compliance-Integrated AI to support audit and regulatory processes [6]. Market Context - The global clinical trials market is projected to exceed $70 billion by 2027, creating a demand for tools that can reduce trial failures, improve patient recruitment, and manage costs [4]. - The platform aims to address these industry needs with scalable, real-time analytics [4]. Distinctive Capabilities - The platform features continuous intelligence, end-to-end automation, multi-trial orchestration, and cost-outcome integration for unified decision support [7]. - It draws on over 500,000 SmartHealth scans, achieving approximately 95% accuracy for vital-sign detection [8].